Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | ITGAL | P20701 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20526419 | 0.98 | KDM4E (0.35) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL448708 | 0.78 | KDM4E (0.35) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL231835 | 0.76 | KDM4E (0.34) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| Methane SCHEMBL28958627 | 0.76 | KDM4E (0.34) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| Benzofuran SCHEMBL20184214 | 0.74 | — | — | |
| SCHEMBL21858488 | 0.73 | POLB (0.33) | MAPT | |
| SCHEMBL44525 | 0.69 | LMNA (0.35) | ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL16399898 | 0.68 | ABCG2 (0.42) | KDM4EABCG2ITGB2ICAM1ITGAL | |
| Pyridine SCHEMBL19136006 | 0.68 | TSHR (0.32) | — | |
| Acetic Acid SCHEMBL11660742 | 0.68 | GAA (0.35) | KDM4EMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1372 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572384-B2 | Unusual substrates of tubulin tyrosine ligase | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2023-02-07 | — | — | US | claimed |
| US-20190144493-A1 | UNUSUAL SUBSTRATES OF TUBULIN TYROSINE LIGASE | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2019-05-16 | — | — | US | claimed |
| WO-2017186855-A1 | UNUSUAL SUBSTRATES OF TUBULIN TYROSINE LIGASE | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2017-11-02 | — | — | WO | claimed |
| EP-1581476-B1 | AMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-16 | — | — | EP | claimed |
| EP-2423212-B1 | PROCESS FOR PRODUCTION OF 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2016-06-01 | — | — | EP | claimed |
| EP-2542528-B1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2013-06-19 | — | — | EP | claimed |
| EP-1784173-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC BONE DISEASES CONTAINING ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES | KOREA RES INST CHEM TECH (KR) | 2012-01-18 | — | — | EP | claimed |
| US-7579352-B2 | Retinoic acid mimetic anilides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-25 | — | — | US | claimed |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | claimed |
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | GLAXO GROUP LIMITED | 2008-04-17 | — | — | US | claimed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | claimed |
| US-6060469-A | Spiro-piperidine derivatives and their use as tachykinin antagonists | MERCK SHARP & DOHME LTD. (GB) | 2000-05-09 | — | — | US | claimed |
| CN-1046270-C | Pyrimidine-thloalkyl and alkylether compounds | PHARMACIA UPJOHN COMPANY (US) | 1999-11-10 | — | — | CN | claimed |
| WO-1999032098-A2 | COMBINATION OF A RAMBA AND A TOCOPHEROL | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-07-01 | — | — | WO | claimed |
| WO-1999029674-A1 | RETINOIC ACID MIMETIC ANILIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-06-17 | — | — | WO | claimed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | claimed |
| EP-0825988-A1 | FUNGICIDAL CYCLIC AMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-03-04 | — | — | EP | claimed |
| WO-1996036616-A1 | FUNGICIDAL CYCLIC AMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-11-21 | — | — | WO | claimed |
| CN-1134697-A | Pyrimidine-sulfanyl and alkyl ether compounds | UPJOHN CO (US) | 1996-10-30 | — | — | CN | claimed |
| EP-0393738-A1 | Hydroxyalkylfuranyl derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-10-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | SLC1A1, SLC6A7, SLC1A2 | KDM4E 1931/4885MEN1 3855/4885ALDH1A1 1291/4885 |
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | SLC6A7, SLC6A5, SLC1A2 | KDM4E 2626/4885MEN1 3372/4885ALDH1A1 1381/4885 |
| US-11572384-B2 | Unusual substrates of tubulin tyrosine ligase | TTL, TUBA1C, TUBB6 | KDM4E 3557/4885MEN1 3206/4885ALDH1A1 3975/4885 |
| US-20190144493-A1 | UNUSUAL SUBSTRATES OF TUBULIN TYROSINE LIGASE | TTL, TUBA1C, TUBB6 | KDM4E 3557/4885MEN1 3206/4885ALDH1A1 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.